Renal Cell Carcinoma: Molecular Aspects.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Clear cell renal cell carcinoma (ccRCC) is the predominant kidney cancer subtype, representing over 85% of cases.
• ccRCC pathogenesis is centrally linked to biallelic VHL gene inactivation, leading to hypoxia-inducible factor (HIF) activation.
• This activation triggers signaling pathways like RAS/MEK/ERK, PI3K/AKT/mTOR, and NF-κB, driving tumor cell proliferation and migration.

Purpose of the Study:

• To elucidate the complex molecular mechanisms underlying ccRCC development.
• To identify key genetic alterations and signaling pathways involved in ccRCC pathogenesis beyond VHL inactivation.
• To understand the interplay between different molecular events in ccRCC for future therapeutic strategies.

Main Methods:

• Review of recent studies on ccRCC molecular signatures.
• Analysis of genetic mutations in chromatin modifiers (PBRM1, SETD2, BAP1) and signaling proteins (PTEN, mTOR).
• Investigation of alternative signaling pathways such as STAT and Sonic Hedgehog (SHH) in ccRCC.

Main Results:

• VHL inactivation alone is insufficient for tumor induction.
• Mutations in chromatin modifiers and signaling proteins, alongside STAT and SHH pathway activation, are frequently observed.
• SHH pathway reactivation can drive tumor formation independently of VHL status, highlighting molecular complexity.

Conclusions:

• ccRCC development is a multifactorial process involving VHL inactivation and additional genetic alterations.
• Cooperative signaling between pathways like HIF and STAT, and independent pathways like SHH, contribute to tumor progression.
• A comprehensive understanding of ccRCC's intricate molecular landscape is crucial for developing effective targeted therapies.